CAY10435
CAY10435 is a β-ketooxazapyridine, selective FAAH inhibitor with antimicrobial activity. CAY10435 binds non-competitively to the FAAH of Dictyostelium discoideum with a Kd value of 0.57 nM.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 288862-73-7
- 分子式: C18H26N2O2
- 分子量:302.41
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-110138
PDP-EAActive Compound -
HY-118210
PHOP -
HY-18544
AA38-3Serine Hydrolase Inhibitor -
HY-123863
SSR411298FAAH Inhibitor -
HY-121558
JP104FAAH Inhibitor -
HY-139384
FAAH inhibitor 2Fatty Acid Amide Hydrolase Inhibitor -
HY-103337
N-ArachidonoylserotoninFAAH Inhibitor/TRPV1 Antagonist -
HY-121090
FAAH-IN-9 -
HY-103462
TC-F2FAAH Inhibitor -
HY-N7062
JNJ-1661010FAAH Inhibitor -
HY-116710
3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinoneFAAH Inhibitor -
HY-118158
FAAH/MAGL-IN-4FAAH/MGL Inhibitor
生物活性
製品説明
IC50 & Target
Ki: 0.57 nM (FAAH, Dictyostelium discoideum)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| COS-7 | IC50 |
0.017 μM
Compound: 65, CAY10435
|
Inhibition of human recombinant FAAH overexpressed in African green monkey COS7 cells using [3H]-anandamide as substrate preincubated for 10 mins before substrate addition measured after 10 mins by liquid scintillation counting analysis
Inhibition of human recombinant FAAH overexpressed in African green monkey COS7 cells using [3H]-anandamide as substrate preincubated for 10 mins before substrate addition measured after 10 mins by liquid scintillation counting analysis
|
[PMID: 24083878] |
化学情報
-
CAS 番号 288862-73-7
-
分子量 302.41
-
分子式 C18H26N2O2
-
SMILES
CCCCCCCCCCCC(C1=NC2=NC=CC=C2O1)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
[1]. Hayes AC, et al. Identification of N-acylethanolamines in Dictyostelium discoideum and confirmation of their hydrolysis by fatty acid amide hydrolase. J Lipid Res. 2013 Feb;54(2):457-66. [Content Brief]
[2]. Glaser ST, et al. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain. J Pharmacol Exp Ther. 2006 Mar;316(3):1088-97. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
CAY10435 関連分類
HY-120650 関連分類
Powered by Bioz